Abstract
128
Objectives In the current report we are illustrating results concerning the use of parametric analyses at baseline and interim PET for predicting treatment response and disease outcome in patients affected by MPM.
Methods We analysed data derived from 86patients (M:F=60:26;mean age 67years) affected by MPM and enrolled in our Institution from December2006 till May2013. Patients had been investigated with PET at baseline and after 2cycles of chemotherapy, whereas response assessment was determined according to modified-RECIST based on best-CT response after treatment. With a median follow-up of 17.5months, for each patient we calculated disease-control rate(DCR), progression-free survival(PFS), and correlated results with parametrical data at PET, i.e. SUVmax, Metabolic Tumor Volume(MTV), Total Lesion Glycolysis(TLG), %SUVmax and %TLG variations.
Results Disease control was obtained in 89.3% of the patients, and median PFS for the entire cohort resulted 8months. On Logrank test there was a significant difference in PFS between patients with radiological progression and those with PRorSD (2 Vs 9months;p<.0001). Most parametrical data at baseline and interim PET (SUVmax, MTV and TLG) showed a statistically significant correlation with radiological response and PFS(p<.05). In particular, the significance appeared higher for baseline parameters and PFS(p<.001), whereas interim data resulted more predictive to treatment response on CT-scan(p<.001). Also %SUVmax at interim PET resulted associated to disease-control with a mean variation of -10% for PR&SD and +33.5% for PD(p=.004). None of the analyses made documented a significant correlation between %TLG at interim and treatment response or PFS.
Conclusions As expected most parametrical data at baseline and interim PET correlate with treatment response and disease outcome in MPM patients.